FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					_			0. 110		50.	прапу Аст	0. 20 .0		_					
1. Name and Address of Reporting Person*  Nolan Mangini Siobhan					<u>N</u>	2. Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC									5. Relationship of Report (Check all applicable) Director			rting Person(s) to Issuer 10% Owner	
					·	NGM ]								X	Officer ( below)	give title		Other (s below)	pecify
(Last) (First) (Middle)							Date of Earliest Transaction (Month/Day/Year)							-	President and CFO				
C/O NGM BIOPHARMACEUTICALS, INC.						03/02/2023													
333 OYSTER POINT BOULEVARD																			
(Street)					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
FRANCISCO CA 94080													'	Form filed by More than One Reporting Person				I	
(City)	(S	state)	(Zip)																
		Ta	ble I - Nor	า-Deriv	/ativ	/e S	ecurities	s Ac	quired,	Dis	posed c	of, or Be	nef	icially	Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D							2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Dispo			ties Acquii d Of (D) (In:			Securities Beneficia Owned F	curities For neficially (D)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	nt (A) or Pi		Price	Transacti				(Instr. 4)
Common Stock 03/02					2/2023		A		76,000	,000 <sup>(1)</sup> A		\$0.00	76,000			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	action 3A. Deemed Execution Date, ay/Year) if any		4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title ar of Securi Underlyir Derivativ (Instr. 3 a	ties 1g e Sec		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				C	ode	v	(A)		Date Exercisab		Expiration Date	Title	or Nur	ount mber Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$4.36	03/02/2023			A		228,000		(2)	C	03/01/2033	Common Stock	22	8,000	\$0.00	228,00	00	D	
Stock Option (Right to Buy)	\$4.36	03/02/2023			A		200,000		(3)	(	03/01/2033	Common Stock	20	0,000	\$0.00	200,00	00	D	

## Explanation of Responses:

- 1. Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
- 2. The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
- 3. 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date

## Remarks:

/s/ Valerie Pierce, Attorney-in-

<u>fact</u>

03/06/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.